TQB2825 clinical trials
How each study uses TQB2825 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TQB2825 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TQB2825 Injection
- 2
Studies by the year they started
5 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
R-CHOP Regimen (1) · Gemcitabine-oxaliplatin regimen (1)
Studies
Open first, then newest update. How each study uses TQB2825 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06829771Written as TQB2825 injection +R-CHOP regimen
- Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaNot yet recruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07187960Written as TQB2825 Injection
- Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological MalignanciesNot yet recruitingPhase 1Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07110194Written as TQB2825 Injection (Subcutaneous Injection)
- Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaRecruitingPhase 2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT06854445Written as TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection
- Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological TumorsStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT05489276Written as TQB2825 injection